Cargando…

Weight gain in patients starting Dolutegravir-based ART according to baseline CD4 count after 48 weeks of follow up

BACKGROUND: Excessive weight gain is a current concern among People Living with HIV (PLHIV) starting ART. OBJECTIVES: To evaluate the weight gain after 48-weeks of ART in naive patients, according with baseline CD4 count. METHODS: PLHIV starting 3TC + TDF + DTG with at least 48-weeks of follow up in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cardoso-Neto, Érico C., Netto, Eduardo Martins, Brites, Carlos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10569987/ https://www.ncbi.nlm.nih.gov/pubmed/37788801 http://dx.doi.org/10.1016/j.bjid.2023.102807

Ejemplares similares

Weight gain on dolutegravir: Association is not the same as causation
por: Maartens, Gary, et al.
Publicado: (2023)

Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks
por: Rolle, Charlotte-Paige, et al.
Publicado: (2023)

Factors Associated With Weight Gain in People Treated With Dolutegravir
por: Taramasso, Lucia, et al.
Publicado: (2020)

DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks)
por: Hidalgo-Tenorio, Carmen, et al.
Publicado: (2022)

Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials
por: Raffi, François, et al.
Publicado: (2015)

Weight gain during the dolutegravir transition in the African Cohort Study
por: Esber, Allahna L., et al.
Publicado: (2022)

Reduction in the weight, gained due to dolutegravir, following switch to bictegravir
por: Saple, Dattatray, et al.
Publicado: (2022)

Dolutegravir–lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study
por: Cahn, Pedro, et al.
Publicado: (2017)

A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks’ observational data
por: Capetti, Amedeo F., et al.
Publicado: (2017)

Weight gain during pregnancy among women initiating dolutegravir in Botswana
por: Caniglia, Ellen C., et al.
Publicado: (2020)

Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL’HIV trial
por: Sculier, Delphine, et al.
Publicado: (2020)

Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)
por: De Miguel, Rosa, et al.
Publicado: (2020)

Coinfection by Hepatitis C Is Strongly Associated with Abnormal CD4/CD8 Ratio in HIV Patients under Stable ART in Salvador, Brazil
por: Brites-Alves, Clara, et al.
Publicado: (2015)

Concentration-Response Relationships of Dolutegravir and Efavirenz with Weight Change After Starting Antiretroviral Therapy
por: Griesel, Rulan, et al.
Publicado: (2022)

Blood glucose outcomes of anti-retroviral therapy naïve Ugandan people with HIV with pre-diabetes mellitus initiated on dolutegravir for 48 weeks
por: Mulindwa, Frank, et al.
Publicado: (2023)

CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz
por: Griesel, Rulan, et al.
Publicado: (2020)

Dolutegravir is not associated with weight gain in antiretroviral therapy experienced geriatric patients living with HIV
por: Guaraldi, Giovanni, et al.
Publicado: (2021)

Evaluating Diversity in Randomized Clinical Trials of Dolutegravir-Based Antiretroviral Therapy Regimens: Pooled 48-Week Analyses by Race, Sex, and Regional Subgroups
por: Rawlings, M Keith, et al.
Publicado: (2022)

48-Week effectiveness and tolerability of dolutegravir (DTG) + lamivudine (3TC) in antiretroviral-naïve adults living with HIV: A multicenter real-life cohort
por: Cabello-Ubeda, Alfonso, et al.
Publicado: (2022)

Absence of Proviral Human Immunodeficiency Virus (HIV) Type 1 Evolution in Early-Treated Individuals With HIV Switching to Dolutegravir Monotherapy During 48 Weeks
por: Jörimann, Lisa, et al.
Publicado: (2023)

Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults
por: Mulindwa, Frank, et al.
Publicado: (2023)

Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults
por: Mulindwa, Frank, et al.
Publicado: (2023)

Growth, weight gain and BMI in virally suppressed children on antiretroviral therapy with specific reference to dolutegravir
por: Belfrage, Erik, et al.
Publicado: (2023)

72. Massive Weight Gain in People with HIV (PWH) Starting Initial Antiretroviral Therapy (ART): Risk Factors and Predictive Ability of Early Weight Gain
por: Phupitakphol, Tanit, et al.
Publicado: (2021)

Performance analysis of an ICU according to GiViTI's StART approach
por: Rosi, R, et al.
Publicado: (2010)

1582. Dolutegravir/Rilpivirine STR Switch Study in Persons with HIV-1 and Chronic Kidney Disease: 48-week Assessment of Viral Suppression, Treatment Adherence and Quality of Life
por: Kwakwa, Helena, et al.
Publicado: (2023)

48-Week Efficacy and Safety of Dolutegravir Relative to Commonly Used Third Agents in Treatment-Naive HIV-1–Infected Patients: A Systematic Review and Network Meta-Analysis
por: Patel, Dipen A., et al.
Publicado: (2014)

48 week bone marker changes with Dolutegravir (DTG) plus Abacavir/Lamivudine (ABC/3TC) vs. Tenofovir/Emtricitabine/Efavirenz (EFV/TDF/FTC): the SINGLE trial
por: Yazdanpanah, Y, et al.
Publicado: (2014)

Low variation in initial CD4 cell count in a HIV referral center, in Salvador, Brazil, from 2002 to 2015
por: Pereira, Marcela Fonseca, et al.
Publicado: (2018)

Laboratory adverse events and discontinuation of therapy according to CD4(+) cell count at the start of antiretroviral therapy
por: Jose, Sophie, et al.
Publicado: (2014)

541. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Treatment Naïve Patients: Week 48 Results in Subgroups Based on Baseline Viral Load, CD4(+) Count, and WHO Clinical Staging
por: Spinner, Christoph D, et al.
Publicado: (2018)

Comparative Changes of Lipid Levels in Treatment-Naive, HIV-1-Infected Adults Treated with Dolutegravir vs. Efavirenz, Raltegravir, and Ritonavir-Boosted Darunavir-Based Regimens Over 48 Weeks
por: Quercia, Romina, et al.
Publicado: (2015)

Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial
por: Llibre, Josep M, et al.
Publicado: (2022)

EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis
por: Vannucchi, Alessandro M., et al.
Publicado: (2019)

Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study
por: Zash, Rebecca, et al.
Publicado: (2018)

Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial
por: van Lelyveld, Steven F. L., et al.
Publicado: (2015)

Efficacy of Dolutegravir versus Darunavir in Antiretroviral First-Line Regimens According to Resistance Mutations and Viral Subtype
por: Salvo, Pierluigi Francesco, et al.
Publicado: (2023)

The promise of paediatric dolutegravir
por: Golin, Rachel, et al.
Publicado: (2021)

Brief Report: Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO Study
por: van Wyk, Jean, et al.
Publicado: (2021)

Consistent efficacy of B/F/TAF in treatment-naïve HIV patients across different baseline HIV-1 RNA levels at week 48
por: He, Kun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rcb1g7vmr56r7kmm9apmtse2l6